Submit Your Feeds

Business News • PR NewsWire • Long-Term Follow Up Data For Pacritinib Presented At 2016 ASCO Annual Meeting

Long-Term Follow Up Data For Pacritinib Presented At 2016 ASCO Annual Meeting
Long-Term Follow Up Data For Pacritinib Presented At 2016 ASCO Annual Meeting

SEATTLE, June 7, 2016 /PRNewswire/ -- CTI BioPharma Corp. (CTI BioPharma) (NASDAQ and MTA:CTIC) today announced long-term safety and efficacy results from the pivotal Phase 3 PERSIST-1 trial evaluating pacritinib versus best available therapy, excluding treatment with JAK2 inhibitors...

View More : http://www.prnewswire.com/news-releases/long-term-follow-up-data-for-pacritinib-presented-at-2016-asco-annual-meeting-30...
Releted News by prnewswire
Global and China Lithium Battery Anode Materials Industry Report, 2016-2020
Long-Term Follow Up Data For Pacritinib Presented At 2016 ASCO Annual Meeting
INGDAN.com Partners with Intel on Building Robotics Ecosystem
New Survey Finds Millennials Most Likely to Rely on Mom for Health Information
Prezi Business Reinvents Presentations for the Modern Workforce
Home Sitemap Contact Us
© businessNewsNewsNews.com